N,N-dimethylformamide
Identification
- Name
- N,N-dimethylformamide
- Accession Number
- DB01844
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
Purchasing individual compounds or compound libraries for your research?
Learn More- Structure
Structure for N,N-dimethylformamide (DB01844)
- Weight
- Average: 73.0938
Monoisotopic: 73.052763851 - Chemical Formula
- C3H7NO
- Synonyms
- Dimethylformamide
- N-Formyldimethylamine
- N,N-Dimethylmethanamide
- External IDs
- NCI-C60913
- NSC-5356
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UChymotrypsin-like elastase family member 1 Not Available Humans URenin Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tertiary carboxylic acid amides. These are compounds containing an amide derivative of carboxylic acid, with the general structure RN(R1)C(R2)=O (R1-R2 any atom but H).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acid derivatives
- Direct Parent
- Tertiary carboxylic acid amides
- Alternative Parents
- Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Tertiary carboxylic acid amide
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- formamides (CHEBI:17741) / a small molecule (CPD-581)
Chemical Identifiers
- UNII
- 8696NH0Y2X
- CAS number
- 68-12-2
- InChI Key
- ZMXDDKWLCZADIW-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H7NO/c1-4(2)3-5/h3H,1-2H3
- IUPAC Name
- N,N-dimethylformamide
- SMILES
- CN(C)C=O
References
- Synthesis Reference
Masao Saito, Kinichi Mizuno, Yuzi Onda, Tetsuo Aoyama, Kumiko Kato, "Process for producing dimethylformamide." U.S. Patent US4218398, issued August, 1933.
US4218398- General References
- Redlich CA, Beckett WS, Sparer J, Barwick KW, Riely CA, Miller H, Sigal SL, Shalat SL, Cullen MR: Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6. [PubMed:3358569]
- External Links
- Human Metabolome Database
- HMDB0001888
- KEGG Compound
- C03134
- PubChem Compound
- 6228
- PubChem Substance
- 46506036
- ChemSpider
- 5993
- ChEBI
- 17741
- ChEMBL
- CHEMBL268291
- ZINC
- ZINC000000901648
- PDBe Ligand
- DMF
- Wikipedia
- Dimethylformamide
- PDB Entries
- 1apv / 1apw / 1oc7 / 1ppk / 1thn / 2foc / 3euz / 3h6f / 3h6i / 3hfa … show 41 more
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) -60.4 °C PhysProp boiling point (°C) 153 °C PhysProp water solubility 1E+006 mg/L (at 25 °C) ISHOW (NA--) @2ND logP -1.01 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 725.0 mg/mL ALOGPS logP -0.77 ALOGPS logP -0.63 ChemAxon logS 1 ALOGPS pKa (Strongest Basic) -0.65 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 20.31 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 19.77 m3·mol-1 ChemAxon Polarizability 7.69 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9673 Blood Brain Barrier + 0.9899 Caco-2 permeable + 0.6997 P-glycoprotein substrate Non-substrate 0.8365 P-glycoprotein inhibitor I Non-inhibitor 0.974 P-glycoprotein inhibitor II Non-inhibitor 0.9886 Renal organic cation transporter Non-inhibitor 0.8896 CYP450 2C9 substrate Non-substrate 0.8113 CYP450 2D6 substrate Non-substrate 0.8469 CYP450 3A4 substrate Non-substrate 0.5749 CYP450 1A2 substrate Non-inhibitor 0.8893 CYP450 2C9 inhibitor Non-inhibitor 0.9489 CYP450 2D6 inhibitor Non-inhibitor 0.9749 CYP450 2C19 inhibitor Non-inhibitor 0.9693 CYP450 3A4 inhibitor Non-inhibitor 0.9814 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9399 Ames test Non AMES toxic 0.9133 Carcinogenicity Carcinogens 0.6893 Biodegradation Not ready biodegradable 0.6188 Rat acute toxicity 1.4483 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9716 hERG inhibition (predictor II) Non-inhibitor 0.9463
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Acts upon elastin.
- Gene Name
- CELA1
- Uniprot ID
- Q9UNI1
- Uniprot Name
- Chymotrypsin-like elastase family member 1
- Molecular Weight
- 27797.995 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor binding
- Specific Function
- Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of b...
- Gene Name
- REN
- Uniprot ID
- P00797
- Uniprot Name
- Renin
- Molecular Weight
- 45057.125 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Nomiyama T, Haufroid V, Buchet JP, Miyauchi H, Tanaka S, Yamauchi T, Imamiya S, Seki Y, Omae K, Lison D: Insertion polymorphism of CYP2E1 and urinary N-methylformamide after N,N- dimethylformamide exposure in Japanese workers. Int Arch Occup Environ Health. 2001 Sep;74(7):519-22. [PubMed:11697456]
- Kim TH, Kim SG: Clinical outcomes of occupational exposure to n,n-dimethylformamide: perspectives from experimental toxicology. Saf Health Work. 2011 Jun;2(2):97-104. doi: 10.5491/SHAW.2011.2.2.97. Epub 2011 Jun 30. [PubMed:22953193]
- Jiang H, Zhang X, Shen J, Zhang Y, Gu Y, Tian T, Chu M, Zhuang X, Lian Y: Association between CYP2E1 and GOT2 gene polymorphisms and susceptibility and low-dose N,N-dimethylformamide occupational exposure-induced liver injury. Int Arch Occup Environ Health. 2019 Apr 16. pii: 10.1007/s00420-019-01436-1. doi: 10.1007/s00420-019-01436-1. [PubMed:30993423]
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/linkouts/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/linkouts/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/linkouts/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/linkouts/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/linkouts/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/linkouts/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/linkouts/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/linkouts/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/linkouts/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/linkouts/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/linkouts/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/linkouts/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/linkouts/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/linkouts/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/linkouts/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/linkouts/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/linkouts/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/linkouts/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/linkouts/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/linkouts/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates